Kerala Court Directs Patanjali Ayurved's Baba Ramdev And Managing Director To Appear Before It In Misleading Advertisements Case

Update: 2024-05-22 04:35 GMT
Click the Play button to listen to article

A Kerala Court has directed Patanjali Ayurved Co-founder Baba Ramdev and its Managing Director Acharya Balkrishna to appear before it on June 03, 2024 in a case of publishing misleading advertisements in English and Malayalam newspapers.The order was issued by Judicial First-Class Magistrate Court in Kozhikode. The Drugs Inspector, Office of the Assistant Drugs Controller, Kozhikode filed...

Your free access to Live Law has expired
Please Subscribe for unlimited access to Live Law Archives, Weekly/Monthly Digest, Exclusive Notifications, Comments, Ad Free Version, Petition Copies, Judgement/Order Copies.

A Kerala Court has directed Patanjali Ayurved Co-founder Baba Ramdev and its Managing Director Acharya Balkrishna to appear before it on June 03, 2024 in a case of publishing misleading advertisements in English and Malayalam newspapers.

The order was issued by Judicial First-Class Magistrate Court in Kozhikode.

The Drugs Inspector, Office of the Assistant Drugs Controller, Kozhikode filed a complaint in Kozhikode Court against Divya Pharmacy which markets the products of Patanjali. The case has been filed under Section 3 of The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. Section 3 prohibits the advertisement of certain drugs for the treatment of certain diseases and disorders.

The specific allegation was misleading advertisements were published claiming that “Divya Lipdom” tablet manufactured by Divya Pharmacy claimed to reduce abnormal levels of cholesterol and fat in the body and to improve fat metabolism. And, the product “Nutrella Diabetic Care” manufactured by Patanjali Ayurved claims to manage blood sugar levels and body weight. 

The complaint alleges violation of Section 3(b) and 3 (d) of The Drugs and Magic Remedies (Objectionable Advertisements) Act. Section 3 (b) prohibits advertisements of drugs claiming maintenance or improvement of the capacity of human beings for sexual pleasure. Section 3 (d) prohibits advertisements of drugs that claim the diagnosis, cure, mitigation, treatment or prevention of any disease, disorder or condition of diseases provided in the Rules made under the Act. 

specified in the Schedule, or any other disease, disorder or conditionRecently, Patanjali Ayurved products were under the scrutiny of the Supreme Court for publishing misleading advertisements against modern systems of medicines like Allopathy. The Court later issued a contempt notice to Patanjali Ayurved for continuing to publish such misleading advertisements that disparage allopathy and make false claims about curing certain diseases.

Case Name: The Drugs Inspector v M/s Divya Pharmacy

Filing Number: 732/2024

Tags:    

Similar News